Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.

Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.

Abstract: Embodiments provided herein, provide for polypeptides and molecules comprising a polypeptide having protease activity and a variant Fc molecule, pharmaceutical compositions comprising the same, and methods that can be used to treat disorders, such as IgG mediated disorders.

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.

Abstract: The present disclosure provides a method, device, and system for deploying a wireless headset based on a third-party platform. The method includes: receiving, by a third-party platform, a headset list sent by a base station, and selecting a headset based on the headset list for deployment; after deploying the headset, sending deployment information of the headset and authentication information of the third-party platform to the base station, to enable the base station to feed back an authentication result based on the deployment information and the authentication information; and obtaining a deployment result of the headset based on the authentication result. This reduces a difficulty in deploying a wireless headset and improves universality of deploying the wireless headset.

Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Abstract: Provided herein are assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12. Also provided herein are recombinant nucleic acids for the improved expression of functional metalloproteinases ADAMTS-7 and nucleic acids for the improved expression of functional metalloproteinases ADAMTS-12. In addition, provided herein are peptide substrates (e.g. FRET substrates) for use in assays for the detection and characterization of modulators of ADAMTS-7 and/or ADAMTS-12.

Abstract: A device and a method for generating a machine translation model and a machine translation device are disclosed. The device inputs a source training sentence of a source language and a dictionary data to a generator network so that the generator network outputs a target training sentence of a target language according to the source training sentence and the dictionary data. Then, the device inputs the target training sentence and a correct translation of the source training sentence to a discriminator network so as to calculate an error between the target training sentence and the correct translation according to the output of the discriminator network, and trains the generator network and the discriminator network respectively. The trained generator network is the machine translation model.

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating brain cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.

Abstract: The present invention discloses a high-moisture sludge ultra-fine synchronizing deep-drying device and a method thereof. The device has a sludge ultrafine pulverizing unit and a sludge drying unit arranged horizontally in parallel, and a pulverized sludge discharge port arranged between them. The sludge ultrafine pulverizing unit comprises a sludge pulverizing chamber and a sludge feeding port, and the sludge pulverizing chamber is a hollow cylindrical structure with a pulverizing rotation shaft arranged in the center, and the pulverizing rotation shaft is provided with a sludge pulverizing impeller. The lower part of the sludge feeding port is provided with a first baffle and/or a second deflector. The sludge is pulverized into sludge powders in the sludge pulverizing chamber, and then fed into the sludge drying chamber to be fluidized and dried. The present invention has the advantage of high drying efficiency, etc.

Abstract: A device and a method for generating a machine translation model and a machine translation device are disclosed. The device inputs a source training sentence of a source language and a dictionary data to a generator network so that the generator network outputs a target training sentence of a target language according to the source training sentence and the dictionary data. Then, the device inputs the target training sentence and a correct translation of the source training sentence to a discriminator network so as to calculate an error between the target training sentence and the correct translation according to the output of the discriminator network, and trains the generator network and the discriminator network respectively. The trained generator network is the machine translation model.

Abstract: The present invention discloses a high-moisture sludge ultra-fine synchronizing deep-drying device and a method thereof. The device has a sludge ultrafine pulverizing unit and a sludge drying unit arranged horizontally in parallel, and a pulverized sludge discharge port arranged between them. The sludge ultrafine pulverizing unit comprises a sludge pulverizing chamber and a sludge feeding port, and the sludge pulverizing chamber is a hollow cylindrical structure with a pulverizing rotation shaft arranged in the center, and the pulverizing rotation shaft is provided with a sludge pulverizing impeller. The lower part of the sludge feeding port is provided with a first baffle and/or a second deflector. The sludge is pulverized into sludge powders in the sludge pulverizing chamber, and then fed into the sludge drying chamber to be fluidized and dried. The present invention has the advantage of high drying efficiency, etc.

Abstract: The disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Abstract: A uniform-distribution filling mechanism for medicinal powder includes a metering disk, a powder storage ring, and a lateral powder blocker. One end of the blocker is provided with a pointed tip, and the other end thereof is provided with a sloping stage. The middle portion of the metering disk is provided with a support shaft, said shaft and the blocker being connected one to the other by means of a support arm. Medicinal powder enters via the pointed tip of the blocker, is evenly agitated, exits via the sloping stage of the blocker, and is evenly dispensed. Thus, the powder is able to enter one side of the blocker and come out the other side thereof such that the powder is evenly dispensed and then uniformly distributed onto the metering disk.

Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Abstract: The present invention generally relates to methods, assays and kits to maintain a human stem cell population in an undifferentiated state by inhibiting the expression or function of METTL3 and/or METTL4, and m6A fingerprint methods, assays, arrays and kits to assess the cell state of a human stem cell population by assessing m6A levels (e.g. m6A peak intensities) of a set of target genes disclosed herein to determine if the stem cell is in an undifferentiated or differentiated state.

Abstract: A uniform-distribution filling mechanism for medicinal powder includes a metering disk, a powder storage ring, and a lateral powder blocker. One end of the blocker is provided with a pointed tip, and the other end thereof is provided with a sloping stage. The middle portion of the metering disk is provided with a support shaft, said shaft and the blocker being connected one to the other by means of a support arm. Medicinal powder enters via the pointed tip of the blocker, is evenly agitated, exits via the sloping stage of the blocker, and is evenly dispensed. Thus, the powder is able to enter one side of the blocker and come out the other side thereof such that the powder is evenly dispensed and then uniformly distributed onto the metering disk.

Abstract: The present invention relates to therapeutic agents comprising miR-138, a miR-138 mimic, a SIN3A RNAi molecule, or a an anti-SIN3A RNAi molecule, and/or an anti-SIN3A antisense oligonucleotide (ASO) or other agent that suppresses SIN3A expression, a small molecule drug that interferes with SIN3A activity or whose actions mimic the biological effects of SIN3A suppression and methods of use of these therapeutic agents to treat cystic fibrosis.